Name | Number of supported studies | Average coverage | |
---|---|---|---|
natural killer cell | 12 studies | 23% ± 7% | |
CD16-positive, CD56-dim natural killer cell, human | 9 studies | 26% ± 11% | |
non-classical monocyte | 7 studies | 24% ± 10% | |
pericyte | 4 studies | 21% ± 5% | |
fibroblast | 3 studies | 30% ± 4% |
Insufficient scRNA-seq data for expression of CHST2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
thymus | 100% | 1611.22 | 651 / 653 | 98% | 95.03 | 593 / 605 |
brain | 99% | 2743.16 | 2619 / 2642 | 98% | 37.15 | 693 / 705 |
lung | 100% | 1747.30 | 576 / 578 | 76% | 30.89 | 873 / 1155 |
kidney | 100% | 1578.96 | 89 / 89 | 72% | 22.41 | 645 / 901 |
ovary | 84% | 1060.62 | 151 / 180 | 79% | 21.55 | 341 / 430 |
prostate | 99% | 1729.47 | 243 / 245 | 54% | 8.76 | 271 / 502 |
uterus | 82% | 1070.65 | 139 / 170 | 65% | 26.46 | 300 / 459 |
skin | 67% | 2468.78 | 1209 / 1809 | 73% | 21.23 | 344 / 472 |
bladder | 81% | 1451.19 | 17 / 21 | 52% | 16.76 | 262 / 504 |
breast | 95% | 1392.17 | 435 / 459 | 31% | 5.62 | 351 / 1118 |
esophagus | 57% | 431.54 | 820 / 1445 | 66% | 29.50 | 121 / 183 |
adrenal gland | 69% | 491.71 | 178 / 258 | 44% | 10.39 | 102 / 230 |
intestine | 79% | 728.06 | 762 / 966 | 29% | 4.68 | 153 / 527 |
spleen | 100% | 3963.89 | 241 / 241 | 0% | 0 | 0 / 0 |
adipose | 99% | 1653.30 | 1195 / 1204 | 0% | 0 | 0 / 0 |
peripheral blood | 97% | 1965.83 | 901 / 929 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 97% | 61.88 | 28 / 29 |
stomach | 51% | 341.70 | 182 / 359 | 44% | 7.34 | 126 / 286 |
tonsil | 0% | 0 | 0 / 0 | 78% | 22.94 | 35 / 45 |
heart | 70% | 497.70 | 600 / 861 | 0% | 0 | 0 / 0 |
pancreas | 5% | 32.32 | 17 / 328 | 42% | 6.93 | 74 / 178 |
blood vessel | 35% | 222.88 | 465 / 1335 | 0% | 0 | 0 / 0 |
liver | 8% | 42.31 | 17 / 226 | 6% | 1.48 | 25 / 406 |
muscle | 11% | 53.90 | 91 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 11% | 1.99 | 9 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0005975 | Biological process | carbohydrate metabolic process |
GO_0006044 | Biological process | N-acetylglucosamine metabolic process |
GO_0006954 | Biological process | inflammatory response |
GO_0006790 | Biological process | sulfur compound metabolic process |
GO_0018146 | Biological process | keratan sulfate biosynthetic process |
GO_1903238 | Biological process | positive regulation of leukocyte tethering or rolling |
GO_0005802 | Cellular component | trans-Golgi network |
GO_0000139 | Cellular component | Golgi membrane |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005794 | Cellular component | Golgi apparatus |
GO_0008146 | Molecular function | sulfotransferase activity |
GO_0001517 | Molecular function | N-acetylglucosamine 6-O-sulfotransferase activity |
Gene name | CHST2 |
Protein name | Carbohydrate sulfotransferase 2 (EC 2.8.2.-) (Galactose/N-acetylglucosamine/N-acetylglucosamine 6-O-sulfotransferase 2) (GST-2) (N-acetylglucosamine 6-O-sulfotransferase 1) (GlcNAc6ST-1) (Gn6ST-1) |
Synonyms | GN6ST |
Description | FUNCTION: Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) as sulfonate donor to catalyze the transfer of sulfate to position 6 of non-reducing N-acetylglucosamine (GlcNAc) residues within keratan-like structures on N-linked glycans and within mucin-associated glycans that can ultimately serve as SELL ligands. SELL ligands are present in high endothelial cells (HEVs) and play a central role in lymphocyte homing at sites of inflammation. Participates in biosynthesis of the SELL ligand sialyl 6-sulfo Lewis X and in lymphocyte homing to Peyer patches. Has no activity toward O-linked sugars. Its substrate specificity may be influenced by its subcellular location. Sulfates GlcNAc residues at terminal, non-reducing ends of oligosaccharide chains. . |
Accessions | Q9Y4C5 ENST00000309575.5 [Q9Y4C5-1] |